Source/Disclosures
Published by:
Wirta D, et al. Dry eye signs, symptoms and quality of life improvements associated with AR-15512 administration. Presented at the Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver.
Disclosures: Wirta reports receiving a grant from Aerie Pharmaceuticals as the principal investigator for this study.
DENVER – A large Phase 2b study has shown that using Aerie Pharmaceuticals’ compound AR-15512 resulted in improved tear production and dry eye symptoms at 7 days and 14 days, according to David Wirtone, MD, from the Eye Research Foundation.
The cold thermoreceptor agonist TRPM8 affects receptors in the conjunctiva, cornea and eyelid to stimulate a feeling of coldness in the eye, resulting in reflex tearing, Wirta said.
Association for research in vision and ophthalmology
Comments are closed.